Spectrum launches Marqibo and ships first commercial orders Spectrum Pharmaceuticals announced the launch of Marqibo. The company also confirmed the shipment of its first commercial orders for Marqibo which are available to patients in the U.S. The company also announced two ongoing phase 3 trials evaluating Marqibo in additional indications. Spectrum obtained world-wide marketing rights to Marqibo through the recent acquisition of Talon Therapeutics.
News For SPPI From The Last 14 Days
Check below for free stories on SPPI the last two weeks.